Polar Asset Management Partners Inc. Vera Therapeutics, Inc. Transaction History

Polar Asset Management Partners Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$13.71 - $19.64 $1.74 Million - $2.49 Million	-126,600 Reduced 48.26%	135,755 $1.86 Million
Q2 2023 Aug 14, 2023	SELL	$6.11 - $17.83 $230,010 - $671,210	-37,645 Reduced 12.55%	262,355 $4.21 Million
Q1 2023 May 15, 2023	SELL	$5.41 - $18.3 $616,740 - $2.09 Million	-114,000 Reduced 27.54%	300,000 $2.33 Million
Q4 2022 Feb 14, 2023	SELL	$15.74 - $22.19 $1.72 Million - $2.43 Million	-109,400 Reduced 20.9%	414,000 $8.01 Million
Q3 2022 Nov 14, 2022	BUY	$13.27 - $22.31 $3.04 Million - $5.11 Million	229,100 Added 77.85%	523,400 $11.2 Million
Q2 2022 Aug 15, 2022	BUY	$12.82 - $23.4 $3 Million - $5.48 Million	234,300 Added 390.5%	294,300 $4.01 Million
Q1 2022 May 16, 2022	BUY	$17.8 - $28.06 $1.07 Million - $1.68 Million	60,000 New	60,000 $1.41 Million

184

55.1M

134K

156K

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $1.15B
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

Get notified when there are updates to the investment portfolio of Polar Asset Management Partners Inc., based on Form 13F filings with the SEC.

Stay updated on Polar Asset Management Partners Inc. with notifications on news.